CJC-1295 and sermorelin are built on the same GHRH(1-29) sequence and act on the same receptor — the difference is how long each one lasts, and what that does to the GH pulse.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | CJC-1295 | Sermorelin |
|---|---|---|
| Class | Modified GHRH(1-29) analog | Native GHRH(1-29) fragment |
| Receptor | GHRH receptor (GHRHR) | GHRH receptor (GHRHR) |
| Half-life | ~30 min (no DAC) / ~6–8 days (DAC) | ~minutes |
| GH release pattern | Pulsatile (no DAC) / sustained (DAC) | Discrete physiologic pulse |
| Pulsatility preserved | Yes (no DAC) / blunted (DAC) | Yes |
| Key modification | DPP-4-resistant substitutions ± albumin-binding DAC | None (unmodified fragment) |
| Pituitary feedback | Preserved | Preserved (somatostatin feedback intact) |
| FDA approval | None (research compound) | Approved 1990 (Geref), since discontinued |
| Commonly paired with | A GHRP (e.g. ipamorelin) | A GHRP |
Sermorelin is the first 29 amino acids of GHRH — the shortest fragment that keeps full GH-releasing activity. It binds GHRHR on pituitary somatotrophs, activating the cAMP cascade to release the body’s own GH in a short, discrete pulse. That brevity is a feature: it preserves the natural somatostatin feedback loop and circadian rhythm of GH secretion.
CJC-1295 starts from that same backbone but adds DPP-4-resistant substitutions and, in the DAC form, a Drug Affinity Complex that binds serum albumin — extending the half-life to roughly 6–8 days (Teichman et al., 2006). The trade-off is physiologic: sustained GHRHR exposure raises baseline GH and IGF-1 but blunts the pulsatility that sermorelin keeps intact.
These are the same molecule family at two ends of a duration spectrum. Sermorelin offers the most physiologic, pulse-preserving profile and has an actual (if discontinued) approval history; CJC-1295 with DAC offers sustained elevation at the cost of natural pulsatility. Both are studied alongside a GHRP, where GHRH and ghrelin-receptor signals converge for a larger combined pulse. Neither is a current FDA-approved therapy for the uses discussed here.
Both are GHRH analogs that stimulate the pituitary to release growth hormone. Sermorelin is the native GHRH(1-29) fragment with a half-life of minutes, producing a short pulse. CJC-1295 is a stabilized version of the same backbone; with a DAC it binds albumin and lasts roughly 6–8 days.
Sermorelin. Its short half-life produces a discrete GH pulse that preserves the natural somatostatin feedback loop. CJC-1295 with DAC raises baseline GH and IGF-1 but blunts that pulsatility.
Sermorelin was approved in 1990 (Geref) for GH-deficiency evaluation and pediatric use but was later discontinued commercially. CJC-1295 is a research compound and is not FDA-approved. This page is a research and educational reference.
GHRH analogs (like these) and GHRPs act on different receptors on the same pituitary cells. Combining them is studied for synergistic GH release that exceeds either alone.